课题基金 / 基金详情

Identification of small molecules that improve trafficking of NLGN4X/Y for autism

Identification of small molecules that improve trafficking of NLGN4X/Y for autism
鉴定可改善自闭症 NLGN4X/Y 运输的小分子
批准号：
10688963
负责人：
Mark Henderson
金额：
$14.62万
依托单位：
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/10688963
关键词：
Cell LineCell surfaceCellsCollaborationsDiseaseExtramural ActivitiesGoalsInformaticsModelingPharmaceutical ChemistryProcessProteinsResearchTranslationsUnited States National Institutes of HealthWorkautism spectrum disorderbasedrug discoveryhigh throughput screeningimprovednovelscreeningsmall moleculesmall molecule therapeuticstherapeutic developmenttrafficking

项目摘要

项目成果

Mark Henderson的其他基金

相似基金

相关文献

中文摘要
翻译
该合作团队旨在通过发现NLGN 4X/Y运输到细胞表面的新型调节剂来建立以前的研究。 NLGN 4X/Y是一种与自闭症有关的蛋白质。早期翻译分支（ETB）的总体目标是通过合作研究模式发现新的小分子疗法并促进治疗开发过程。在每次合作中，NIH和校外疾病专家都与ETB药物发现团队合作，后者提供小分子筛选，药物化学和信息学专业知识。 在此期间，该团队开发了一种基于细胞的NLGN 4X/Y贩运高通量筛选策略，并生成了用于进行筛选的细胞系。
英文摘要
This collaborative team aims to build on previous research by uncovering novel modulators of NLGN4X/Y trafficking to the cell surface. NLGN4X/Y is a protein that is implicated in autism. The Early Translation Branch's (ETB) overall goal is to uncover new small molecule therapeutics and catalyze the process of therapeutic development through a model of collaborative research. With each collaboration, NIH and extramural disease experts work with the ETBs drug discovery teams, who provide access to small molecule screening, medicinal chemistry and informatics expertise. During this period, the team has developed a strategy for a cell-based high-throughput screen of NLGN4X/Y trafficking and generated cell lines to perform the screen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Cell-Based Assay to Identify Small Molecules for Galactocerebrosidase (GALC)
Identifying small molecules with selective toxicity towards muscle invasive prostate cancer cells
Evaluation of CD206 agonists in diabetic retinopathy
Evaluation of cAbl allosteric inhibitors in Gaucher-Parkinson
海外基金